Long-term follow-up of people with Duchenne muscular dystrophy who received delandistrogene moxeparvovec
Monitors long-term safety in people who previously received delandistrogene moxeparvovec for Duchenne muscular dystrophy.
Plain-language title generated from the registry record
Registry title: A Long-term Follow-up Study of Participants Who Received Delandistrogene Moxeparvovec (SRP-9001) in a Previous Clinical Study
Key facts
- Where
- Aurora, Baltimore, Boston, Chicago, Columbus, Dallas, Durham, Gainesville, Iowa City, Little Rock, Los Angeles, Milwaukee, New York, Norfolk, Palo Alto, Philadelphia, Portland, Rochester, Sacramento, Salt Lake City, San Diego, and St Louis, United StatesSee the 22 sites
- Phase
- Phase 3
Where in United States
- Children's Hospital of ColoradoAurora, United StatesNo longer taking part
- The Johns Hopkins Hospital, Rubenstein Child Health BldgBaltimore, United StatesNo longer taking part
- Boston Children's HospitalBoston, United StatesNo longer taking part
- Ann & Robert H. Lurie Children's Hospital of ChicagoChicago, United StatesNo longer taking part
- Nationwide Children's HospitalColumbus, United StatesNo longer taking part
- Children's Health Specialty CenterDallas, United StatesNo longer taking part
- Lenox Baker Children's Hospital (Duke University)Durham, United StatesNo longer taking part
- University of Florida Clinical Research CenterGainesville, United StatesNo longer taking part
- University of Iowa ICTS Clinical Research UnitIowa City, United StatesNo longer taking part
- Arkansas Children's HospitalLittle Rock, United StatesNo longer taking part
- UCLA Medical CenterLos Angeles, United StatesNo longer taking part
- Children's Hospital WisconsinMilwaukee, United StatesNo longer taking part
- Columbia University Pediatric Neuromuscular CenterNew York, United StatesNo longer taking part
- Children's Hospital of The King's DaughtersNorfolk, United StatesNo longer taking part
- Lucile Packard Children's Hospital Stanford (LPCH)Palo Alto, United StatesNo longer taking part
- Chiildren's Hospital of PhiladelphiaPhiladelphia, United StatesNo longer taking part
- Oregon Health and Science UniversityPortland, United StatesNo longer taking part
- University of Rochester Medical CenterRochester, United StatesNo longer taking part
- University of California - DavisSacramento, United StatesNo longer taking part
- University Of Utah HealthSalt Lake City, United StatesNo longer taking part
- Rady Children's HospitalSan Diego, United StatesNo longer taking part
- Washington University School of MedicineSt Louis, United StatesNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Sarepta Therapeutics, Inc.
- Trial code
- NCT05967351EU 2023-505043-39-00
- Record updated
- 6 February 2026
- Original description
The purpose of this study is to provide a single clinical study with a uniform approach to monitoring long-term safety and efficacy in participants who received delandistrogene moxeparvovec in a previous clinical study. No study drug will be administered as part of this study.Read full original descriptionShow less
A Phase 3, Multinational, Long-term Follow-up Study to Evaluate Safety and Efficacy in Subjects Who Have Previously Received SRP-9001 in a Clinical Study
The purpose of this study is to provide a single clinical study with a uniform approach to monitoring long-term safety and efficacy in participants who received delandistrogene moxeparvovec in a previous clinical study. No study drug will be administered as part of this study.
Inclusion: Received delandistrogene moxeparvovec for Duchenne muscular dystrophy in a previous clinical study; Has (a) parent(s) or legal caregiver(s) or is ≥18 years of age and able to understand and comply with the study visit schedule and all other protocol requirements.
Exclusion: Not applicable.